February 22, 2013 2:44 PM | 1 min read |
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
In a report published Friday, Bank of America reiterated its Buy rating on Onyx Pharmaceuticals (NASDAQ: ONXX), and slightly raised its price target from $99.00 to $100.00.Bank of America noted, “There were three positives to ONXX's 4Q report: (1) 4Q Kyprolis sales of $45.3M were ahead of the $43.5M previously preannounced, implying strong new patient starts during the quarter vs. our model. (2) First quarterly Stivarga royalties of $8.2M were well ahead of our $1.2M estimate, and while driven by bolus patients first coming on therapy, shows this product will provide better incremental cashflows than our prior estimates. (3) ONXX disclosed an 8% royalty rate it receives on PFE's exciting new breast cancer drug candidate '991, ahead of midsingle digit % expectations. ONXX gave soft 2013 Kyprolis guidance of steady Q/Q sales growth, which implies at least $190-$200M in annual sales.”Onyx Pharmaceuticals closed on Thursday at $69.93.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.